Preclinical studies performed in appropriate models could help identify optimal timing of combined chemotherapy and immunotherapy.

ABSTRACT: Immune checkpoint inhibitors (ICI) have been revolutionary in the field of cancer therapy. However, their success is limited to specific indications and cancer types. Recently, the combination treatment of ICI and chemotherapy has gained more attention to overcome this limitation. Unfortunately, many clinical trials testing these combinations have provided limited success. This can partly be attributed to an inadequate choice of preclinical models and the lack of scientific rationale to select the most effective immune-oncological combination. In this review, we have analyzed the existing preclinical evidence on this topic, which is only limitedly available. Furthermore, this preclinical data indicates that besides the selection of a specific drug and dose, also the sequence or order of th

SUBMITTER: Berckmans Y 

PROVIDER: S-EPMC10512939 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature